Soluble CD26/30 levels before and after treatment with interferon-alpha and ribavirin combination therapy in a pediatric hepatitis C patient

Journal of Microbiology, Immunology and Infection

Volumn 37, Issue 1, 2004, Pages 67-70

  Liao, Yu Ru ^a   Po Yen, Chen ^a   Lin, Chieh Chung ^a   Fu, Lin Shien ^a   Chiu, Chen Chia ^b   Chi, Ching Shiang ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

CD26; CD30; Hepatitis C; Interferon alpha; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; CD30 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ARTICLE; CASE REPORT; CHRONIC HEPATITIS; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; ECHOGRAPHY; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; MALE; PEDIATRICS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; SERUM; SOLUBILITY; TREATMENT OUTCOME;

ANTIGENS, CD26; ANTIGENS, CD30; CHILD; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; RIBAVIRIN; SOLUBILITY; TREATMENT OUTCOME;

EID: 1842783133     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Marcellin P. Hepatitis C: clinical spectrum of the disease. J Hepatol 1999;31(Suppl 1):9-16.
2. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
3. Hijikata M, Kato N, OotsuyamaY, Nakagawa M, Ohkoshi S, Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991;175:220-8.
4. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
5. Chang MH. Chronic hepatitis virus infection in children. J Gastroenterol Hepatol 1998;13:541-8.
6. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26:(Suppl 1):S2-10.
7. Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000;19:23-30.
8. Francavilla R, Mieli-Vergani G. Treatment of hepatitis C virus infection in children. Can J Gastroenterol 2000;14 (Suppl B): S41-4.
9. Del Prete G, De Carli M, Almerigogna F, Daniel CK, D'Elios MM, Zancuoghi G, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995;9:81-6.
10. Willheim M, Ebner C, Baier K, Kern W, Schrattbauer K, Thien R, et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J Allergy Clin Immunol 1997;100:348-55.
11. Leonard C, Tormey V, Faul J, Burke CM, Poulter LW. Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy 1997;27:780-6.
12. Bengtsson A, Holm L, Back O, Fransson J, Scheynius A. Elevated serum levels of soluble CD30 in patients with atopic dermatitis. Clin Exp Immunol 1997;109:533-7.
13. Gerli R, Bistoni O, Lunardi C, Giacomelli R, Tomassini C, Biagini P, et al. Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. Rheumatology 1999;38:1282-4.
14. Hoshimoto K, Ohta N, Ohkura T, Inaba N. Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Thl/ Th2 balance? Gynecol Obstet Invest 2000;50:260-3.
15. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-41.
16. Gonzalez-Peralta RP, Davis GL, Lau JY. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994;21:255-9.
17. Foschi FG, Gramenzi A, Castelli E, Cursaro C, Pagani S, Margotti M, et al. Soluble CD30 serum level in HCV-positive chronic active hepatitis: a surrogate marker of disease activity? Cytokine 2000;12:815-8.
18. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997;159:1012-8.
19. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
20. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32 (Suppl 1):98-112.
21. Lee SD, Chan CY, Wang YJ, Wu JC, Lai KH, Tsai YT, et al. Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology 1991;13:830-3.
22. Wu JS, Lu CF, Liu WT, Lin SY. Prevalence of antibodies to hepatitis C virus (anti-HCV) in different populations in Taiwan. Zhongua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1991;24:55-60.
23. Memon MI, Memon MA. Hepatitis C: an epidemiological review. J Viral Hepat 2002;9:84-100.
24. Jonas MM. Treatment of chronic hepatitis C in pediatric patients. Clin Liver Dis 1999;3:855-67.
25. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
26. Lamprecht P, Moosig F, Gause A, Herlyn K, Csemok E, Hansen H, et al. Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2001;60:385-90.
27. Firneisz G, Lakatos PL, Szalay F; Hungarian Viral Hepatitis Study Group. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand J Gastroenterol 2001;36:877-80.